• 1
    Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl. 4):1-46.
  • 2
    Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-7.
  • 3
    Emsley R, Oosthuizen PP, Koen L et al. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 2012;73:e541-7.
  • 4
    Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res 2007;95:19-29.
  • 5
    Emsley R, Chiliza B, Asmal L et al. The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50.
  • 6
    World Federation of Mental Health. Keeping care complete: caregivers' perspectives on mental illness and wellness. An international survey. World Federation of Mental Health, 2006.
  • 7
    Wiersma D, Nienhuis FJ, Slooff CJ et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24:75-85.
  • 8
    Emsley R, Oosthuizen P, Koen L et al. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol 2013;33:80-3.
  • 9
    Drake RJ. Insight into illness: impact on diagnosis and outcome of nonaffective psychosis. Curr Psychiatry Rep 2008;10:210-6.
  • 10
    Winklbaur B, Ebner N, Sachs G et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006;8:37-43.